The hospital is among 90 sites testing to see whether the prospective vaccine made by Moderna is safe and protects people against the coronavirus. The Cambridge biotech’s vaccine is among 11 candidates worldwide that have entered late-stage clinical trials.
“We want our study and enrollment to be representative of the epidemic and the communities disproportionately impacted,” said Baden, who is also one of three leaders of the national study.
Since the study began in the first week of August, Brigham and Women’s has recruited “many hundreds” of participants, he said, adding that he was not free to say exactly how many. Recruitment is continuing and is likely to be completed in “weeks, if not sooner,” Baden said.
Half the participants enrolled nationwide will receive the vaccine candidate, and half will get a placebo, in two injections 28 days apart. Then researchers will watch to see if those who received the